NYSE: QGEN

Qiagen (QGEN) Stock Analysis & Forecast

Nov 13 close

$49.89−0.21 (−0.4%)

Gekko Brief

AI summaryNov 9 close

Qiagen's quarterly results dominate the week's news, with net income for the three months ended 30 September 2026 falling 19% to USD 105.66 million even as net sales rose, alongside more than double the prior restructuring and acquisition expenses. Separately, the company reported choosing Medrio EDC for its in vitro diagnostic studies, and shareholders approved Jonathan M. Pratt as Managing Director following his move into the CEO role on 1 September 2026. Several voting rights disclosures from MFS, JPMorgan and Bank of America also surfaced this week as background filings.

Qiagen shares closed at $50.55, up 0.4%, sitting above both the 50-day ($45.98) and 200-day ($42.53) moving averages, with the 50-day above the 200-day. The stock has gained 11.4% over one month, 18.5% over three months and 54.9% over six months, trading within a 52-week range of $32.53 to $57.82. The GekkoIndex reads 46, placing it in the Neutral zone, while the price sits 8.2% below the Gekko Fair Value of $55.05.

The next earnings date falls on 3 February 2027, 85 days out, placing it beyond a typical 20-trading-day holding window. Across the last 8 quarters, Qiagen has beaten estimates 5 times, with the most recent report on 4 November 2026 showing an EPS of $0.65 against an estimate of $0.63 and a 1% reaction. Seasonality from this point in the calendar has averaged a 4.9% move over the next 20 trading days across 5 years, with gains in 3 of them. No insider, Congress, or unusual options activity appears in the respective windows, though one trailblazer holder is recorded.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Qiagen price vs fair value

$52.28$49.89Nov ’25May ’26Nov ’26
Close $49.89200-day averageGekko Fair Value $52.28

Qiagen quick facts

Market cap
$10.30B
P/E ratio
27.1
Forward P/E
15.6
EPS, TTM
$1.85
Revenue, TTM
$2.12B
Profit margin
18.2%
Dividend yield
0.70%
Beta
0.56
Volume
1.64M avg 6.69M
1-year return
+12.0%
Typical daily move
±0.6%
Typical 20-day move
±4.5%
50-day average
$46.50
200-day average
$42.45
Next earnings
Feb 3
Shares outstanding
206.5M
52-week range
$32.53$57.82

Qiagen swing-trade checklist

Qiagen scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $49.89 is above the 50-day ($46.50) and 200-day ($42.45) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    51.1, Neutral

    Reading 51.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    4.6% below

    Price is within 5% of Gekko Fair Value (4.6% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 80 days

    Next report Feb 3, 2027, 80 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +6.3% on average

    From this point in the calendar, the next 20 trading days averaged +6.3% over 5 years, rising in 5 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Qiagen stock chart and price history

Qiagen closed at $49.89 on Nov 13, 2026, +12.0% over the past year, inside a 52-week range of $32.53 to $57.82.

Close50-day average200-day averageVolume
Qiagen share price, past year, with 50-day and 200-day moving averages and volume$35$40$45$55DecJan 2026FebMarAprMayJunJulAugSepOctNov49.89

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+8.1%
3 months
+17.1%
6 months
+51.3%
1 year
+12.0%
The full QGEN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open QGEN in Gekko

Follow Qiagen through every session

Put QGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track QGEN in GekkoFree for 7 days. No credit card required.

About Qiagen

Qiagen focuses on converting raw biological specimens into readable molecular information for laboratories worldwide. It is known for kits and devices that isolate and purify DNA and RNA from samples, plus diagnostic consumables used in tuberculosis screening, monitoring transplant patients, prenatal checks, and identifying HPV and other sexually transmitted infections. Its catalog also includes PCR-based research products, tools for human identification and forensic work, and next-generation sequencing items like gene panels and library preparation reagents.

The business is built around three pillars: disposable consumables, laboratory instruments, and digital tools, giving customers both the reagents and the hardware needed to run tests, plus bioinformatics platforms and cloud-based software for analyzing outcomes. Buyers include diagnostic labs and life sciences researchers working across genomics, infectious disease detection, and forensic genealogy applications.

Qiagen traces back to 1984 and operates out of Venlo in the Netherlands. Its stock trades on the NYSE under the ticker QGEN.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
qiagen.com

Qiagen GekkoIndex: the smart money zone

Qiagen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.1, in the Neutral zone, up 4.9 points over five sessions.

010051.1Neutral

Up 4.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying65−0.6%−0.2%+2.9%+3.1%
Accumulation2050.0%−0.5%−0.5%+2.0%
Neutral (current zone)399+0.6%+1.1%+1.3%+1.1%
Distribution30−2.1%−3.1%−5.6%−10.4%
Selling3Too few readings yet

Average QGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the QGEN price, zone by zone.Track QGEN in Gekko

Is Qiagen stock overvalued? Gekko Fair Value

Qiagen trades 4.6% below Gekko Fair Value of $52.28, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Qiagen shares are worth, recalculated every trading day.

$52.28

Gekko Fair Value, Nov 14, 2026

4.6% below fair value · About fair value

At the end of Aug 2026 the price was 17.1% below the estimate.

Gekko Fair ValueShare price, month end
$52$50Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open QGEN in Gekko

Qiagen insider and Congress trading

No open-market insider purchases were filed for Qiagen, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for QGEN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every QGEN insider filing, plotted on the chart in Gekko.Open QGEN in Gekko

Congress trades last 90 days

No trades in QGEN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for QGEN, plotted on the chart in Gekko.Open QGEN in Gekko

Buybacks

Qiagen has been buying back its own shares.

Bought back, quarter ended Mar 31, 2026
$496.7M
As a share of market cap
4.82%
Trailing four quarters
$519.1M

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds QGEN.

1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Qiagen earnings: next date and track record

Qiagen reports on Feb 3, 2027 (80 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±2%average move across the report
1 of 8reports followed by a gain

Share-price move across each report

−2.1%Feb ’250.0%May ’25−5.5%Aug ’25−3.6%Nov ’25−1.3%Feb ’26−1.4%May ’26−1.4%Aug ’26+1.0%Nov ’26
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$0.65
est $0.63
+3.7%$548.0M
est $538.6M
+1.7%+1.0%
Aug 5, 2026$0.62
est $0.60
+3.7%$535.0M
est $527.5M
+1.4%−1.4%
May 6, 2026$0.54
est $0.54
0.0%$492.3M
est $496.1M
−0.8%−1.4%
Feb 4, 2026$0.62
est $0.61
+1.6%$540.4M
est $528.4M
+2.3%−1.3%
Nov 4, 2025$0.64
est $0.61
+4.9%$532.6M
est $525.9M
+1.3%−3.6%
Aug 5, 2025$0.60
est $0.60
0.0%$533.5M
est $515.8M
+3.4%−5.5%
May 7, 2025$0.55
est $0.50
+9.3%$483.5M
est $468.9M
+3.1%0.0%
Feb 5, 2025$0.64
est $0.65
−1.5%$521.2M
est $518.5M
+0.5%−2.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Qiagen stock forecast and analyst price targets

Analysts’ average 12-month price target for Qiagen is $49.59, −0.6% from the last close, from 11 firms rating the stock in the last 90 days.

$49.59consensus 12-month target, −0.6% from the last close
Low $48.66High $53
Buy4
Hold7
Sell0

Each firm’s latest rating in the last 90 days: 11 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13UBSHold, reiterated$50+0.2%
Oct 27BarclaysHold, downgraded$53+6.2%
Oct 26CitiHold, maintained$52+4.2%
Oct 22Robert W. BairdBuy, maintained$52+4.2%
Oct 22J.P. MorganHold, downgraded$52+4.2%
+1.3%average 20-day move after past Neutral readings
+6.3%average move over the next 20 trading days in the last 5 years
±0.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Qiagen seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Qiagen averaged +6.3% across the last 5 years, rising in 5 of them.

Next 20 trading days, by year

+1.4%2021+5.6%2022+8.9%2023+7.9%2024+7.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+2.4%4 of 5
Next 10 trading days+4.1%5 of 5
Next 15 trading days+2.7%5 of 5
Next 20 trading days+6.3%5 of 5
Next 30 trading days+6.4%5 of 5

For scale, QGEN’s typical 20-trading-day move in either direction is about 4.5%.

Qiagen market cap and key statistics

Qiagen’s market cap is $10.30B, with a P/E ratio of 27.1 and revenue of $2.12B over the last twelve months.

Valuation

Market cap
$10.30B
P/E ratio
27.1
Forward P/E
15.6
EPS, TTM
$1.85
Gekko Fair Value
$52.28

Trading

Volume
1.64M
Avg volume, 20 days
6.69M
52-week high
$57.82
52-week low
$32.53
Shares outstanding
206.5M

Financials

Revenue, TTM
$2.12B
Profit margin
18.2%
Return on equity
10.8%
Quarterly earnings growth, YoY
−19.2%

Risk and income

Beta
0.56
Typical daily move
±0.6%
Typical 20-day move
±4.5%
Dividend yield
0.70%

Qiagen stock news this week

Coverage of Qiagen this week reads neutral: 4 positive, 8 neutral and 1 negative headlines.

News sentiment neutral

Qiagen peers

Qiagen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Qiagen stock FAQ

What is Qiagen’s market cap?

Qiagen’s market cap is $10.30B at the Nov 13, 2026 close of $49.89, with 206.5M shares outstanding. The shares trade on a P/E ratio of 27.1.

What is the Qiagen stock forecast?

The consensus analyst 12-month price target for Qiagen is $49.59, −0.6% from the last close. Of the 11 firms that rated the stock in the last 90 days, 4 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Qiagen stock overvalued or undervalued?

On Gekko’s estimate Qiagen is about fair value: the Nov 13, 2026 close of $49.89 is 4.6% below Gekko Fair Value of $52.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Qiagen report earnings next?

Qiagen is expected to report on Feb 3, 2027 (80 days away). Analysts expect earnings of $0.66 per share on revenue of $573.2M. Qiagen beat the earnings estimate in 5 of its last 8 reports, moving 2% on average across the report.

What is Qiagen’s 52-week high and low?

Qiagen’s 52-week high is $57.82 and its 52-week low is $32.53; it closed at $49.89 on Nov 13, 2026, +12.0% over the past year. Over the last five years the shares peaked at $58.43 on Nov 26, 2021.

Is Qiagen stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Qiagen the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.